Be part of the knowledge.™

Nephrology

274

LikeLikedUnlike

1-15 of 176

Improving Cardiovascular Care with Timely Chronic Kidney Disease Diagnosis
Conversations in CV Risk Assessment
Improving Cardiovascular Care with Timely Chronic Kidney Disease Diagnosis
- Jennifer Caudle, DO
  Peer
- Dustin Le, MD, MHS
  Peer
- Niloofar Nobakht, MD, FASN
  Peer
Albuminuria and Heart Failure: Connecting the Dots to Optimize Care
Conversations in CV Risk Assessment
Albuminuria and Heart Failure: Connecting the Dots to Optimize Care
- Jennifer Caudle, DO
  Peer
- Robert J. Mentz, MD, FHFSA, FACC, FAHA
  Peer
The Link Between Albuminuria and CV Risk in Non-Diabetic Patients
Conversations in CV Risk Assessment
The Link Between Albuminuria and CV Risk in Non-Diabetic Patients
- Brian P. McDonough, MD, FAAFP
  Peer
- Anuradha Lala-Trindade, MD
  Peer
Albuminuria: An Overlooked Red Flag in Cardiovascular Risk
Conversations in CV Risk Assessment
Albuminuria: An Overlooked Red Flag in Cardiovascular Risk
- Matthew Sorrentino, MD
  Peer
- Ashish Verma, MBBS
  Peer
Uncovering Cardiovascular Risk in Patients with Target Blood Pressure
Conversations in CV Risk Assessment
Uncovering Cardiovascular Risk in Patients with Target Blood Pressure
- Gates B. Colbert, MD
  Peer
- Michael E. Hall, MD
  Peer
- Clyde W. Yancy, MD
  Peer
uACR and eGFR: A Dual-Marker Approach to Cardiovascular Risk Assessment
Conversations in CV Risk Assessment
uACR and eGFR: A Dual-Marker Approach to Cardiovascular Risk Assessment
- Matthew Sorrentino, MD
  Peer
- Ashish Verma, MD
  Peer
advertisement
Rethinking Chronic Kidney Disease: A Key Driver of Cardiovascular Risk
Conversations in CV Risk Assessment
Rethinking Chronic Kidney Disease: A Key Driver of Cardiovascular Risk
- Jennifer Caudle, DO
  Peer
- Dustin Le, MD, MHS
  Peer
- Niloofar Nobakht, MD, FASN
  Peer
The Role of Albuminuria in Assessing Cardiovascular Risk
Conversations in CV Risk Assessment
The Role of Albuminuria in Assessing Cardiovascular Risk
- Brian P. McDonough, MD, FAAFP
  Peer
- Anu Lala, MD
  Peer
Management of Elevated Albuminuria: Examining Therapeutic Pathways
Conversations in CV Risk Assessment
Management of Elevated Albuminuria: Examining Therapeutic Pathways
- Jennifer Caudle, DO
  Peer
- Leslie Gewin, MD, FASN
  Peer
- Robert J. Mentz, MD, FHFSA, FACC
  Peer
Finerenone for CKD in Type 1 Diabetes: Updates from FINE-ONE
Heart Matters
Finerenone for CKD in Type 1 Diabetes: Updates from FINE-ONE
- Janet B. McGill, MD, MA, FACE, FACP
  Peer
Individualized Management of Hyperkalemia: The Role of Potassium Binders in Patients With Cardiorenal Disease
Nephrology
Individualized Management of Hyperkalemia: The Role of Potassium Binders in Patients With Cardiorenal Disease
- Ellie Kelepouris, MD, FACP, FAHA
  Peer
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Nephrology
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
- prof. Hiddo Heerspink
  Peer
advertisement
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
Nephrology
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
- Richard E. Pratley, MD
  Peer
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
Nephrology
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
- prof. Hiddo Heerspink
  Peer
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
Nephrology
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
  Peer

Program Chapters

Segment Chapters

Playlist:

Recommended